CD44 and osteosarcoma: Recently, researchers from the same group developed a bone- and CD44-targeted liposomal drug delivery system by conjugating alendronate and HA as targeting moieties, respectively, to improve the osteosarcoma-targeting ability and specific intracellular drug delivery 34.